J B Chemicals & Pharmaceuticals Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/evk5ajae0c9668dcy5kiireh.pdf

Key Takeaways


Domestic Formulations: Organic Engine & Brand Momentum

Chopra: "100% if you look at the medical fertility and with what we have done in the era of heart failure, the agenda going ahead is to prevent the progression of hypertension to heart failure."

Acquired Portfolios: Integration Payoff & LOE Opportunity

Chopra: "Post LOE, what is going to happen... we will see an influx of around 50, 70 Brands coming in. Overall, the cost of therapy will come down. Volumes over a period of time in the next year should go up by two to three times. So, we see a huge opportunity."
Khanna: "Overall, from a margin standpoint, we will still be at a better position despite this price erosion, because we will be looking at local sourcing options."

CMO Business: Capacity Inflection & Strategic Ambition

Chopra: "We want this business to be close to $100 million for us, and we want this business to contribute mid to long-term 20% to overall JB business."

International Formulations: Steady, With Selective Caution


Margins & Costs: Peaked Pressure, Steady Outlook


Capital Allocation & M&A: Conservative, With Ambition

Kataria: "We are open to acquiring companies as well. It is a matter of, you know, what opportunity comes our way that makes strategic and financial sense."

Guidance & Commitments

CommitmentSpecificsTimeline
Domestic revenue growthContinue to outperform market growth via organic and inorganic mixSustained
EBITDA marginMaintain 24–26% range with focus on revenue growthFY23
MR productivityReach close to INR 6.5 lakhEnd of FY23
CMO lozenge capacityReach 12 crore lozenges/month after packaging debottleneckingNext 2–3 months
CMO lozenge capacityReach 15–16 crore lozenges/monthAfter further debottlenecking (undated)
CMO business sizeClose to $100 million, 20% of overall JB businessMid-to-long term
Export formulations growthMid-teens across marketsRest of FY23
Azmarda LOE cooling periodRestrict to ~2 weeks to liquidate existing stockAt LOE event
Top-line and profit growth aspirationMid-teens top-line (14–16%), profit growth better than top line (16–18%)Next 2–3 years
ESOP costINR 38–40 croreFY24
ESOP costINR 25–30 croreFY25
Gross margin input costsRemain stable at current levelsQ3 and Q4 FY23
International filingsNew product filings to commercialize in existing marketsNext 2–3 years

Key Metrics

MetricQ2 FY23
Revenue₹809 cr, +36% YoY
Domestic revenue₹434 cr
Domestic organic growthMid-teens
International business revenue₹375 cr, +28% YoY
Domestic/international revenue mix46/54
Gross margin63%, flat QoQ, vs 65% in Q2 FY22
Operating EBITDA₹202 cr, +44% YoY from ₹140 cr
Profit after tax₹111 cr, +13% YoY from ₹98 cr
EBITDA margin guidance for FY2324% to 26%
Top-line growth aspiration (2-3 years)14% to 16%
Bottom-line growth aspiration (2-3 years)16% to 18%
CMO revenue growth64% YoY
CMO share of international sales (H1 FY23)28%, up from 20% in FY22
Acquired brands portfolio growth (IQVIA, like-to-like)25%
Sporlac growth (IQVIA)50%, retained #1 rank in covered market
Azmarda growth (IQVIA)46%
Total prescriptions4.12 cr, +55% YoY from 2.65 cr
Monthly prescription run-rate (with acquired portfolio)1.5 cr
Chronic contribution to domestic portfolio~52%, up from ~45% 1-1.5 years ago
MR productivity target (FY23 end)~₹6.5 lakh
Total medical reps2,100 (1,600 organic, 300 Sanzyme, 200 Azmarda)
Borrowings (end of Sep '22)₹350 cr, up from ₹26 cr as of Mar '22
Cash and investments (end of Sep '22)₹203 cr, up from ₹57 cr as of Mar '22
Cash from operations (H1 FY23)~₹280 cr
ESOP cost (Q2 FY23)~₹18 cr
ESOP cost guidance (FY23)~₹71 cr
ESOP cost guidance (FY24)₹38-40 cr
ESOP cost guidance (FY25)₹25-30 cr